Regeneron partners with bluebird on cancer therapies, invests $100 million

The company will use its VelociSuite platform in order to help find human antibodies as well as T cell receptors and bluebird will contribute its expertise in gene transfer and cell therapy

Aug. 7, 2018

Regeneron Pharmaceuticals announced that it will invest $100 million in cancer drug developer bluebird bio. The two companies will then jointly develop new cell therapies for cancer.

The pair will employ Regeneron’s VelociSuite platform for the discovery of human antibodies as well as T cell receptors and bluebird’s gene transfer techniques. Bluebird’s technology focuses on CAR-T therapy.

The companies have chosen six initial targets and will equally share the R&D costs up to the point of submitting an Investigational New Drug (IND) application.

Read the full release